Non-small Cell Lung Cancer Registry

Status Completed

Clinical Trial Summary

This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions develop. This trial is seeking patients 18 years or older that have been diagnosed with Stage IIIB or Stage IV non-small cell lung cancer that cannot be treated by surgery.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00099541
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	November 2004
Completion date	November 2007

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02495233` - A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)	Phase 1/Phase 2
Withdrawn	`NCT02672358` - Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC	Phase 2
Recruiting	`NCT05815472` - Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)	N/A
Not yet recruiting	`NCT05900219` - Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study	Phase 2
Not yet recruiting	`NCT04560244` - A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment	Phase 2
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Completed	`NCT01924416` - Lung Cancer Information Study (LCIS-R01)	N/A
Completed	`NCT01136083` - Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients	N/A
Completed	`NCT00831454` - Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection	N/A
Completed	`NCT00363766` - Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT00913705` - Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer	Phase 3
Completed	`NCT01383135` - Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2	Early Phase 1
Completed	`NCT01124864` - A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.	Phase 2
Completed	`NCT00049998` - Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer	Phase 3
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT03320044` - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting	`NCT04895930` - Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC	Phase 2
Recruiting	`NCT03267654` - Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance	Phase 2
Recruiting	`NCT04401059` - Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study	Phase 4
Not yet recruiting	`NCT02930954` - Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance	Phase 2